Changing lifestyle, medicinal adverse effects, delayed pregnancy, and comorbidities are affecting natural reproduction among the human population. These factors have led to the adoption of in vitro fertilization (IVF) or assisted reproductive treatments across the globe. A woman’s ovary produces a single egg in a menstrual cycle. In IVF, eggs are extracted and fertilized in a laboratory to create zygotes. These zygotes are then cultured in a controlled environment. On attaining the blastocyst stage, these embryos are then transferred to uterus. Physicians insist on extracting maximum number of eggs due to low volatility and high failure rates in fertilization and other IVF procedures. Various medications including pharmaceutical preparations and hormones are administered to induce ovulation and increase egg count.
Prior to recommending IVF, physicians promote natural pregnancy. In some cases, infertility is even linked to abnormality or deficiency in ovulation or egg production. Ovulation inducing medications augment the chances of pregnancy, as these tend to increase the egg count, thereby increasing fertilization possibilities. Ovulation stimulation is one of the first and critical steps in IVF. Rise in number of patients opting for IVF is likely to fuel the growth of the global ovulation inducing drugs market during the forecast period from 2018 to 2026. Moreover, key suppliers are introducing new medications such as recombinant hormones and gonadotropins. This is likely to fuel the growth of the ovulation inducing drugs market. However, high cost of IVF procedure and low success rates are the major factors likely to restrain the global ovulation inducing drugs market. Furthermore, large number of small and medium scale manufacturers of ovulation inducing drugs at regional levels has led to a fragmented ovulation inducing drugs market.
The global ovulation inducing drugs market can be segmented based on drug class, distribution channel, and region. In terms of drug class, the global ovulation inducing drugs market can be bifurcated into hormones and pharmaceuticals. The hormones segment can be classified into follicle stimulating hormone (FSH), human menopausal gonadotropin (hMG), and human chorionic gonadotropin (hCG). hMGs are combination of FSH and luteinizing hormone (LH) offering better efficiency and low adverse effects. The pharmaceuticals segment can be divided into gonadotropin releasing hormone (GnRH) agonists and GnRH antagonists. These drugs stimulate the production of gonadotropin hormones such a FSH and LH to augment the ovulation process. Based on distribution channel, the global ovulation inducing drugs market can be segregated into hospital pharmacies, independent pharmacies, and online pharmacies. In some markets, IVF centers dispense these medications to patients.
Request a Brochure of the Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=44964
In terms of region, the global ovulation inducing drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for the largest share of the global ovulation inducing drugs market during the forecast period, due to high adoption of IVF and ART techniques. Europe is anticipated to account for a significant share of the global ovulation inducing drugs market during the forecast period. Well-established health care infrastructure and trend for fertility tourism in countries in Central and Eastern Europe are the key factors driving the embryo transfer devices market in the region. Increase in expenditure to develop health care infrastructure and rise in private health care expenditure in emerging markets such as China and India are anticipated to boost the market in Asia Pacific. Changing lifestyle and rising rates of infertility are the major factors that contribute to the growth of the ovulation inducing drugs market in developing countries.
Major players operating in the global ovulation inducing drugs market are Sanofi, EMD Serono, Inc., Ferring Pharmaceuticals, Inc., Fresenius Kabi AG, Merck & Co., Inc., Sun Pharmaceuticals Industries Ltd., Serum Institute of India Ltd., and Glenmark Pharmaceuticals Ltd.
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
Email: [email protected]